Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.44 |
| ▸ | PAK4 | O96013 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1445986 | 0.89 | CYP1A2 (0.49) | CYP1A2TAAR1NPC1RAB9AMAPT | |
| SCHEMBL1446069 | 0.89 | CYP1A2 (0.42) | CYP1A2RAB9AMAPTPLK4ADRB3 | |
| SCHEMBL1446501 | 0.87 | CYP1A2 (0.56) | CYP1A2TAAR1NPC1RAB9AMAPT | |
| SCHEMBL1447101 | 0.86 | MAPT (0.47) | NPC1RAB9AMAPTPLK4EPHX2 | |
| SCHEMBL1447134 | 0.85 | CYP1A2 (0.53) | CYP1A2TAAR1NPC1RAB9AMAPT | |
| SCHEMBL1447093 | 0.84 | CYP1A2 (0.53) | CYP1A2TAAR1NPC1RAB9AMAPT | |
| SCHEMBL1445997 | 0.84 | CYP1A2 (0.53) | CYP1A2TAAR1NPC1RAB9AMAPT | |
| SCHEMBL1446011 | 0.83 | CYP1A2 (0.56) | CYP1A2TAAR1NPC1RAB9AMAPT | |
| SCHEMBL1445984 | 0.83 | CYP1A2 (0.53) | CYP1A2TAAR1NPC1RAB9AMAPT | |
| SCHEMBL1446190 | 0.83 | TAAR1 (0.51) | CYP1A2TAAR1NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910743-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-03-22 | — | — | US | claimed |
| US-20090324511-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-12-31 | — | — | US | claimed |
| US-20070066626-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2007-03-22 | — | — | US | claimed |
| US-7910743-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7538223-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20070066626-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324511-A1 | Compounds, Compositions and Methods | TNNI3, TNNC1, TNNT2 | CYP1A2 4662/4885TAAR1 4657/4885NPC1 4608/4885 |
| US-20070066626-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | CYP1A2 4662/4885TAAR1 4657/4885NPC1 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.